The wet age-related macular degeneration (AMD) therapy market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, Novartis’s Beovu, Roche’s Susvimo, and Roche’s Vabysmo—face competition from low-priced off-label Avastin (Roche / Genentech). The approved premium-priced therapies place a substantial burden on payers; therefore, despite being effective and safe, they are subject to payer restrictions. Competition has increased with the launches of Roche’s Vabysmo and Susvimo and will grow further with the launches of Regeneron’s high-dose aflibercept, Kodiak Sciences’ KSI-301, and AbbVie / Regenxbio’s gene therapy RGX-314; these agents may offer a dosing advantage over the currently available VEGF inhibitors and thus address a substantial unmet need. In addition, biosimilar versions of Lucentis began launching in July 2022 and biosimilar versions of Eylea will follow the year after, making it essential to understand how these therapies could impact access to premium-priced brands.
Questions answered
Content highlights
Geography: United States
Primary research: Survey of 99 U.S. ophthalmologists and 31 U.S. managed care organization (MCO) pharmacy and medical directors (PDs / MDs)
Key drugs covered: Avastin, Eylea, Lucentis, Beovu, Vabysmo, Susvimo, high-dose aflibercept, KSI-301, RGX-314
Product description
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.